149 related articles for article (PubMed ID: 1323053)
1. [Primary dexamethasone-suppressible hyperaldosteronism and hyperprolactinemia].
Veglio F; Pinna G; Rabbia F; Mulatero P; Chiandussi L
Minerva Endocrinol; 1992; 17(1):43-6. PubMed ID: 1323053
[TBL] [Abstract][Full Text] [Related]
2. Dopaminergic regulation of aldosterone secretion: assessment in different subtypes of primary aldosteronism and in essential hypertension.
Veglio F; Pinna G; Rabbia F; Panarelli M; Bisbocci D; Melchio R; Chiandussi L
J Int Med Res; 1991; 19(1):44-9. PubMed ID: 1850365
[TBL] [Abstract][Full Text] [Related]
3. Endogenous dopaminergic inhibition of aldosterone and prolactin secretion is apparently not increased in primary aldosteronism.
Jungmann E; Althoff PH; Rosak C; Schwedes U; Schöffling K
Horm Metab Res; 1986 Feb; 18(2):138-40. PubMed ID: 3699687
[TBL] [Abstract][Full Text] [Related]
4. Differing effects of metoclopramide and adrenocorticotropin on plasma aldosterone levels in glucocorticoid-suppressible hyperaldosteronism and other forms of hyperaldosteronism.
Ganguly A; Pratt JH; Weinberger MH; Grim CE; Fineberg NS
J Clin Endocrinol Metab; 1983 Aug; 57(2):388-92. PubMed ID: 6306041
[TBL] [Abstract][Full Text] [Related]
5. Dexamethasone suppressible hyperaldosteronism: insights into adrenal physiology.
Connell JM; Jardine A; Fraser R
Adv Nephrol Necker Hosp; 1990; 19():69-77. PubMed ID: 2154082
[No Abstract] [Full Text] [Related]
6. Effects of metoclopramide, a dopamine antagonist, on secretion of aldosterone and renin release in patients with primary aldosteronism.
Mizuno K; Yamazaki M; Ikeda K; Yaginuma K; Hashimoto S; Fukuchi S
Jpn Heart J; 1983 Nov; 24(6):917-24. PubMed ID: 6323781
[TBL] [Abstract][Full Text] [Related]
7. Study on clinical and endocrine characteristics of dexamethasone-suppressible hyperaldosteronism compared with those in primary aldosteronism owing to aldosterone-producing adenoma.
Yamakita N; Yasuda K; Noritake N; Mercado-Asis LB; Murase H; Mune T; Morita H; Miura K
Acta Endocrinol (Copenh); 1989 Sep; 121(3):334-44. PubMed ID: 2552725
[TBL] [Abstract][Full Text] [Related]
8. [The effect of metoclopramide, a dopamine inhibitor, on aldosterone secretion in patients with primary aldosteronism].
Mizuno K; Yaginuma K; Yamazaki M; Fukuchi S
Nihon Naibunpi Gakkai Zasshi; 1982 Aug; 58(8):976-83. PubMed ID: 6292008
[No Abstract] [Full Text] [Related]
9. Dopamine infusion enhances the adrenocorticotropic hormone and cortisol response to metoclopramide in hyperprolactinemic patients but not in normal subjects.
Moro M; Maraschini C; Cavagnini F
Gynecol Endocrinol; 1997 Jun; 11(3):155-62. PubMed ID: 9209895
[TBL] [Abstract][Full Text] [Related]
10. Dexamethasone-suppressible hyperaldosteronism. Adrenal transition cell hyperplasia?
Connell JM; Kenyon CJ; Corrie JE; Fraser R; Watt R; Lever AF
Hypertension; 1986 Aug; 8(8):669-76. PubMed ID: 3015796
[TBL] [Abstract][Full Text] [Related]
11. Effects of naloxone on the pituitary-adrenal axis in patients with dexamethasone-suppressible hyperaldosteronism.
Fallo F; Boscaro M; Sonino N; Mantero F
Clin Endocrinol (Oxf); 1987 Feb; 26(2):163-8. PubMed ID: 2822294
[TBL] [Abstract][Full Text] [Related]
12. Dexamethasone-suppressible hyperaldosteronism: a large new kindred.
O'Mahony S; Burns A; Murnaghan DJ
J Hum Hypertens; 1989 Aug; 3(4):255-8. PubMed ID: 2552113
[TBL] [Abstract][Full Text] [Related]
13. Dexamethasone suppressible hyperaldosteronism in a child with nephrosclerosis.
Lee SM; Lightner E; Witte M; Oberfield S; Levine L; New MI
Acta Endocrinol (Copenh); 1982 Feb; 99(2):251-5. PubMed ID: 6277130
[TBL] [Abstract][Full Text] [Related]
14. Anomalous postural aldosterone response in glucocorticoid-suppressible hyperaldosteronism.
Ganguly A; Grim CE; Weinberger MH
N Engl J Med; 1981 Oct; 305(17):991-3. PubMed ID: 6268979
[No Abstract] [Full Text] [Related]
15. Hypertension corrected and aldosterone responsiveness to renin-angiotensin restored by long-term dexamethasone in glucocorticoid-suppressible hyperaldosteronism.
Woodland E; Tunny TJ; Hamlet SM; Gordon RD
Clin Exp Pharmacol Physiol; 1985; 12(3):245-8. PubMed ID: 2992855
[TBL] [Abstract][Full Text] [Related]
16. Missing endogenous dopaminergic inhibition of aldosterone secretion in human CONN's adenoma tissue after heterotransplantation to thymusaplastic mice.
Jungmann E; Schwedes U; Usadel KH; Obert I; Schöffling K
Horm Metab Res; 1983 Aug; 15(8):413. PubMed ID: 6311710
[No Abstract] [Full Text] [Related]
17. Dopaminergic inhibition of metoclopramide-induced aldosterone secretion in man. Dissociation of responses to dopamine and bromocriptine.
Carey RM; Thorner MO; Ortt EM
J Clin Invest; 1980 Jul; 66(1):10-8. PubMed ID: 7400305
[TBL] [Abstract][Full Text] [Related]
18. Dopaminergic modulation of aldosterone secretion: effect of sodium balance and postural changes.
García-Robles R; Ruilope L; Mancheño E; Hurtado A; Alcázar JM; Varela C; de la Calle H; Rodicio JL; Sancho J
Rev Esp Fisiol; 1984 Mar; 40(1):63-8. PubMed ID: 6087430
[TBL] [Abstract][Full Text] [Related]
19. Glucocorticoid-suppressible aldosteronism: a disorder of the adrenal transitional zone.
Gomez-Sanchez CE; Gill JR; Ganguly A; Gordon RD
J Clin Endocrinol Metab; 1988 Sep; 67(3):444-8. PubMed ID: 2842358
[TBL] [Abstract][Full Text] [Related]
20. Dexamethasone-suppressible hyperaldosteronism: pathophysiology, clinical aspects, and new insights into the pathogenesis.
Fallo F; Sonino N; Boscaro M; Armanini D; Mantero F; Dörr HG; Knorr D; Kuhnle U
Klin Wochenschr; 1987 May; 65(10):437-44. PubMed ID: 3037179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
